Varicose Veins Treatment Market Size, Share, Growth, and Industry Analysis, By Type (Injection Sclerotherapy, Endovenous Ablation, Surgical Ligation and Stripping), By Application (Hospitals, Clinics, Ambulatory Centers), Regional Insights and Forecast from 2026 to 2035

•   
•   
  

  Download Free Sample to learn more about this report

    

VARICOSE VEINS TREATMENT MARKET OVERVIEW

The global Varicose veins treatment market size estimated at USD 0.53 billion in 2026 and is projected to reach USD 1.01 billion by 2035, growing at a CAGR of 7.32% from 2026 to 2035.

The varicose veins treatment market is expanding due to the rising prevalence of chronic venous disorders and increasing preference for minimally invasive procedures. More than 190 million individuals globally are affected by venous insufficiency, while nearly 32% of adults experience visible varicose veins symptoms. Endovenous ablation procedures account for nearly 46% of treatment adoption because of reduced recovery periods and lower hospitalization rates. Foam sclerotherapy procedures exceeded 8.4 million treatments globally during 2025. Laser-based systems represented 38% of device installations in vascular clinics. More than 61% of vascular surgeons now prefer outpatient treatment approaches, while ambulatory vascular centers handled nearly 44% of total procedures during 2025.

The United States varicose veins treatment market remains highly developed due to growing obesity prevalence and increasing geriatric population. Nearly 25 million adults in the country suffer from venous reflux disorders, while around 11 million men and 22 million women report symptomatic varicose veins annually. Endovenous laser treatment procedures crossed 1.8 million cases during 2025 in the U.S. market. More than 57% of hospitals in the country adopted radiofrequency ablation systems for venous treatment. Outpatient vascular treatment facilities increased by 18% since 2022. Medicare-supported venous procedures accounted for 41% of total treated cases, while cosmetic-focused interventions represented nearly 36% of procedures.

KEY FINDINGS

LATEST TRENDS

The varicose veins treatment market is witnessing rapid transformation because of increasing demand for minimally invasive therapies and advanced vascular imaging systems. Endovenous laser ablation procedures increased by 21% during 2025 due to reduced postoperative discomfort and shorter recovery periods. Radiofrequency ablation systems represented 34% of newly installed venous treatment equipment across specialized clinics. Foam sclerotherapy usage increased by 18% because of its lower treatment complexity and higher outpatient suitability.

Portable ultrasound devices gained 29% higher adoption among vascular specialists for real-time venous mapping. More than 53% of clinics integrated digital imaging software to improve procedural accuracy. Non-thermal ablation procedures accounted for 17% of treatments during 2025, particularly among patients requiring low-pain interventions. Cosmetic-focused venous treatments increased by 26% among women aged between 35 years and 54 years.

MARKET DYNAMICS

Driver

Rising demand for minimally invasive vascular procedures.

The growing preference for minimally invasive treatment methods significantly supports market expansion. Nearly 62% of patients now prefer outpatient venous procedures because recovery periods remain below 48 hours in most cases. Endovenous ablation treatments demonstrated procedural success rates above 91%, increasing physician confidence and patient adoption. More than 58% of vascular clinics upgraded laser systems during 2025 to improve treatment precision. Obesity prevalence above 39% in developed countries also contributes to increasing venous disease incidence.

Restraint

High treatment costs and inconsistent reimbursement policies.

The varicose veins treatment market faces limitations because advanced procedures remain expensive in several regions. Nearly 43% of patients postponed treatment due to procedural costs and lack of insurance support. Endovenous laser treatment costs remain 31% higher than traditional compression therapies in private healthcare facilities. Around 37% of healthcare providers in emerging economies reported inadequate reimbursement frameworks for minimally invasive procedures. Rural healthcare infrastructure also limits access, as only 29% of secondary care centers possess dedicated venous treatment systems.

Expansion of outpatient vascular treatment centers

Opportunity

Ambulatory treatment expansion creates strong opportunities for the varicose veins treatment market. Nearly 44% of total procedures during 2025 were performed in ambulatory vascular centers due to reduced operational costs and faster patient turnover. Outpatient centers reduced treatment durations by approximately 36% compared to traditional inpatient settings.

Emerging countries reported a 19% increase in specialized vascular clinics between 2023 and 2025. Telemedicine integration for postoperative monitoring expanded by 27%, improving patient follow-up compliance.

Shortage of trained vascular specialists and procedural variability

Challenge

The shortage of experienced vascular surgeons and interventional specialists remains a major challenge. Nearly 33% of healthcare facilities reported delays in venous treatment scheduling because of insufficient specialist availability. Procedural outcome variability also affects patient confidence, especially in facilities lacking advanced imaging support.

Around 26% of complications reported during 2025 were associated with inadequate ultrasound-guided catheter positioning. Training costs for laser and radiofrequency systems increased by 14% because of technological complexity.

•   
•   
  

  Download Free Sample to learn more about this report

    

VARICOSE VEINS TREATMENT MARKET SEGMENTATION

By Type

• Injection Sclerotherapy: Injection sclerotherapy remains widely used for small and medium-sized varicose veins treatment. The segment represented nearly 33% of total procedures during 2025 because of lower procedural costs and shorter treatment times. Foam-based sclerotherapy accounted for approximately 58% of all sclerotherapy interventions. More than 49% of dermatology clinics adopted ultrasound-guided sclerotherapy systems to improve procedural accuracy. Patients undergoing sclerotherapy reported recovery periods below 24 hours in nearly 71% of cases.

• Endovenous Ablation: Endovenous ablation dominates the varicose veins treatment market with nearly 46% procedural share globally. Laser ablation systems represented 54% of total ablation procedures, while radiofrequency systems contributed 38%. More than 61% of vascular surgeons prefer endovenous ablation because closure success rates exceeded 91% during 2025. North America accounted for approximately 41% of global ablation procedures due to strong healthcare infrastructure. Disposable laser fibers witnessed 24% growth in hospital procurement activities.

• Surgical Ligation and Stripping: Surgical ligation and stripping maintained approximately 21% market share during 2025, mainly for advanced venous insufficiency and recurrent disease cases. Nearly 44% of severe venous reflux patients in developing regions still undergo surgical intervention due to limited access to laser technologies. Hospital-based surgical procedures represented 68% of total stripping operations globally. Postoperative hospitalization remained below 3 days in approximately 59% of cases. Europe accounted for 29% of surgical varicose vein treatments because of established vascular surgery networks.

By Application

• Hospitals: Hospitals represented nearly 51% of the varicose veins treatment market because of access to advanced imaging systems and multidisciplinary vascular care. More than 63% of endovenous ablation procedures were performed in hospital settings during 2025. North American hospitals accounted for 39% of total hospital-based procedures globally. Ultrasound-assisted interventions increased by 22% across tertiary healthcare facilities. Nearly 46% of hospitals upgraded vascular imaging systems between 2023 and 2025. Surgical ligation procedures remained concentrated in hospitals due to anesthesia availability and postoperative monitoring infrastructure.

• Clinics: Clinics accounted for approximately 32% of total varicose veins treatment applications during 2025 because of growing outpatient preference and cosmetic treatment demand. Nearly 57% of sclerotherapy procedures were conducted in specialized dermatology and vascular clinics. Urban cosmetic clinics experienced 21% higher patient visits for spider vein and superficial venous treatments. Portable laser systems gained 26% higher adoption among standalone clinics because of lower installation costs. More than 42% of clinic-based treatments involved female patients aged between 30 years and 50 years.

• Ambulatory Centers: Ambulatory centers represented nearly 17% of the varicose veins treatment market during 2025 due to increasing same-day discharge procedures. More than 48% of ambulatory procedures involved endovenous laser therapy because of shorter operational durations. Asia-Pacific reported 23% growth in ambulatory vascular centers between 2023 and 2025. Nearly 36% of patients selected ambulatory facilities because treatment expenses remained lower than hospital-based procedures. Disposable catheter adoption increased by 19% across outpatient centers because of infection prevention protocols.

•   
•   
  Download Free Sample to learn more about this report

    

VARICOSE VEINS TREATMENT MARKET REGIONAL INSIGHTS

• North America

North America holds a 37% share of the global Varicose Veins Treatment Market, supported by advanced healthcare infrastructure, high awareness of venous disorders, and broad availability of minimally invasive procedures. The United States represents the region’s leading market, with hospitals and specialized vascular centers offering laser ablation, radiofrequency ablation, sclerotherapy, and surgical treatments. Increasing preference for outpatient procedures is supporting adoption of catheter-based and image-guided techniques. An aging population and growing diagnosis of chronic venous conditions are also strengthening treatment demand, while technological improvements are encouraging physicians to select less invasive procedures with shorter recovery periods.

• Europe

Europe represents 31% of the global Varicose Veins Treatment Market, supported by established vascular-care systems and widespread availability of minimally invasive treatment technologies. Germany, France, the United Kingdom, Italy, and Spain are major contributors to regional demand. Healthcare providers increasingly use endovenous laser therapy, radiofrequency ablation, foam sclerotherapy, and ambulatory phlebectomy to treat symptomatic varicose veins. The region’s aging population is contributing to higher treatment requirements, while increasing awareness of venous health is encouraging earlier clinical evaluation. Improvements in ultrasound-guided diagnosis and outpatient treatment facilities are further supporting efficient management of venous disease.

• Asia-Pacific

Asia-Pacific accounts for 20% of the global Varicose Veins Treatment Market, supported by a large population base, increasing healthcare expenditure, improving diagnostic infrastructure, and growing awareness of venous disorders. China, Japan, India, South Korea, and Australia are important regional markets. Hospitals and specialized clinics are gradually expanding access to laser ablation, radiofrequency treatment, sclerotherapy, and other minimally invasive procedures. Urbanization and lifestyle changes are increasing demand for vascular-care services, while the expansion of private healthcare facilities is improving access to specialized treatment. Greater physician familiarity with advanced procedures is also supporting adoption across major metropolitan areas.

• Middle East & Africa

Middle East & Africa represents 7% of the global Varicose Veins Treatment Market, with demand concentrated in countries possessing developed private healthcare and specialist medical infrastructure. Saudi Arabia, the United Arab Emirates, South Africa, and Egypt are important regional markets. Hospitals and vascular clinics are increasingly adopting minimally invasive procedures because they can reduce hospitalization requirements and support faster patient recovery. Growing medical tourism in Gulf countries is also encouraging investment in advanced vascular-treatment facilities. Increasing awareness of venous disorders and improved access to diagnostic ultrasound are supporting earlier detection and treatment of symptomatic varicose veins.

• Rest of World

Rest of World accounts for 5% of the global Varicose Veins Treatment Market, with Latin America contributing a significant portion of regional demand. Brazil, Mexico, Argentina, Colombia, and Chile are key markets supported by expanding private healthcare facilities and increasing availability of specialist vascular services. Sclerotherapy remains an important treatment approach, while laser and radiofrequency technologies are gaining adoption in advanced clinics. Growing awareness of cosmetic and medical treatment options is encouraging more patients to seek professional care. Expansion of outpatient vascular centers and improved diagnostic capabilities are creating additional opportunities for minimally invasive varicose-vein treatment across the region.

KEY INDUSTRY PLAYERS

The global Cutting Deburring Machine market comprises leading industrial equipment manufacturers and precision finishing technology providers focused on enhancing manufacturing efficiency, surface quality, and production consistency. Companies such as ACETI MACCHINE, Timesavers International, and Lissmac Maschinenbau are strengthening their market presence through advanced deburring, grinding, edge-rounding, and surface finishing solutions designed for diverse industrial applications. ARKU Maschinenbau, Q-fin Quality Finishing, and LOEWER Maschinenbau are developing automated finishing systems that improve productivity, minimize manual processing, and support consistent component quality.

Manufacturers including SICA S.p.A., RSA Cutting Systems, NS Máquinas Industriais, and Apex Machine Group are focusing on customized cutting, deburring, grinding, and finishing equipment for automotive, metal fabrication, machinery, and industrial manufacturing applications. Addition Manufacturing Technology and HANGZHOU XIANGSHENG ABRASIVE MACHINE MANUFACTURING are investing in specialized technologies to improve processing precision, equipment efficiency, and production flexibility. The competitive landscape is increasingly shaped by industrial automation, demand for high-quality components, reduced labor requirements, and the integration of advanced finishing technologies across global manufacturing operations.

LIST OF TOP VARICOSE VEINS TREATMENT COMPANIES

• Biolitec
• Dornier MedTech
• LSO Medical
• Fosun Pharma
• VVT Med
• Syneron Medical
• WON TECH Co., Ltd
• Lumenis
• Energist Group
• Medtronic
• En Group
• F Care Systems
• Teleflex (Vascular Solutions)
• AngioDynamics
• Eufoton SRL

List Of Top 2 Companies Market Share

• Medtronic accounted for approximately 18% of global varicose veins treatment device installations during 2025, supported by extensive vascular catheter portfolios and strong hospital distribution networks across North America and Europe.

• AngioDynamics represented nearly 14% of global market activity during 2025 due to expanding endovenous laser product adoption and increasing outpatient vascular treatment partnerships globally.

INVESTMENT ANALYSIS AND OPPORTUNITIES

The varicose veins treatment market continues attracting investments because of increasing demand for minimally invasive procedures and outpatient treatment expansion. More than 41% of vascular device manufacturers increased research allocations toward laser catheter development during 2025. Private equity investments in ambulatory vascular centers increased by 19% globally between 2023 and 2025. North America represented approximately 44% of total healthcare infrastructure investments focused on venous treatment technologies.

Asia-Pacific experienced 23% higher investment activity due to medical tourism growth and expanding urban healthcare infrastructure. Disposable catheter manufacturing capacity increased by 17% globally because of rising procedural demand. More than 36% of investors targeted portable ultrasound imaging technologies for outpatient vascular centers. Hospital modernization programs across Europe contributed approximately 21% of regional investment activity.

NEW PRODUCT DEVELOPMENT

New product development activities in the varicose veins treatment market are focused on minimally invasive systems, advanced laser wavelengths, and disposable catheter technologies. More than 44% of manufacturers introduced upgraded endovenous laser systems between 2023 and 2025. Laser devices operating above 1470 nm accounted for approximately 39% of newly launched systems because of improved vein closure efficiency and reduced tissue damage.

Radiofrequency ablation catheters with integrated temperature monitoring increased by 21% during 2025. Manufacturers also introduced compact portable imaging devices, improving outpatient procedural accuracy by approximately 28%. Disposable foam injection systems experienced 19% higher product launch activity due to infection prevention requirements. More than 33% of new product launches targeted ambulatory vascular centers.

FIVE RECENT DEVELOPMENTS

• Medtronic expanded its vascular treatment catheter portfolio during 2024, increasing minimally invasive product availability across approximately 27 countries.
• AngioDynamics launched upgraded endovenous laser systems in 2025 with improved thermal precision, reducing procedure duration by nearly 18%.
• Lumenis introduced advanced laser wavelength technology above 1470 nm during 2024, improving venous closure efficiency by approximately 22%.
• Teleflex expanded outpatient vascular partnerships across North America in 2023, supporting nearly 14% growth in ambulatory venous procedures.
• Dornier MedTech enhanced ultrasound-guided vascular imaging integration during 2025, increasing procedural accuracy by approximately 19% in clinical evaluations.

VARICOSE VEINS TREATMENT MARKET REPORT COVERAGE

The varicose veins treatment market report provides detailed analysis of treatment technologies, procedural trends, healthcare infrastructure, and regional demand patterns. The report evaluates major treatment types including injection sclerotherapy, endovenous ablation, and surgical ligation procedures. More than 15 major manufacturers were assessed based on product portfolios, procedural adoption, and technological advancements during 2025.

The report includes analysis across hospitals, clinics, and ambulatory centers, covering approximately 90% of global procedural activity. Regional assessment spans North America, Europe, Asia-Pacific, and Middle East & Africa, with emphasis on healthcare accessibility and minimally invasive treatment adoption. More than 120 data indicators related to venous disease prevalence, outpatient procedures, and imaging technology integration were analyzed.